Tuesday, July 25, 2017

The Pharmacogenomics Journal - Table of Contents alert Volume 17 Issue 4

If you are unable to see the message below, click here to view.
The Pharmacogenomics Journal


Volume 17, Issue 4 (July 2017)

In this issue
Letter to the Editor
Original Articles

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed

November 2-3, 2017 | Hanover, Germany


Letter to the Editor


The CYP2D6 VCF Translator

W Qiao, J Wang, B S Pullman, R Chen, Y Yang and S A Scott

Pharmacogenomics J 2017 17: 301-303; advance online publication, March 15, 2016; 10.1038/tpj.2016.14

Full Text



More than 25 years of genetic studies of clozapine-induced agranulocytosis

S A J de With, S L Pulit, W G Staal, R S Kahn and R A Ophoff

Pharmacogenomics J 2017 17: 304-311; advance online publication, April 18, 2017; 10.1038/tpj.2017.6

Abstract | Full Text

Original Articles


Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study

S Mahurkar, M Moldovan, V Suppiah, M Sorosina, F Clarelli, G Liberatore, S Malhotra, X Montalban, A Antigüedad, M Krupa, V G Jokubaitis, F C McKay, P N Gatt, M J Fabis-Pedrini, V Martinelli, G Comi, J Lechner-Scott, A G Kermode, M Slee, B V Taylor, K Vandenbroeck, M Comabella, F M Boneschi, The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) and C King

Pharmacogenomics J 2017 17: 312-318; advance online publication, March 22, 2016; 10.1038/tpj.2016.20

Abstract | Full Text

The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity

S Hamzic, N Wenger, T K Froehlich, M Joerger, S Aebi, C R Largiadèr and U Amstutz

Pharmacogenomics J 2017 17: 319-324; advance online publication, March 22, 2016; 10.1038/tpj.2016.23

Abstract | Full Text

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters

Y Ma, S Xin, M Huang, Y Yang, C Zhu, H Zhao, Y Zhang, L Chen, Y Zhao, J Li, W Zhuang, X Zhu, L Zhang and X Wang

Pharmacogenomics J 2017 17: 325-330; advance online publication, April 19, 2016; 10.1038/tpj.2016.31

Abstract | Full Text

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab

F S Falvella, C Cremolini, R Miceli, F Nichetti, S Cheli, C Antoniotti, G Infante, A Martinetti, F Marmorino, E Sottotetti, R Berenato, M Caporale, A Colombo, F de Braud, M Di Bartolomeo, E Clementi, F Loupakis and F Pietrantonio

Pharmacogenomics J 2017 17: 331-336; advance online publication, March 22, 2016; 10.1038/tpj.2016.22

Abstract | Full Text

Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients

S Lal, N Sutiman, L L Ooi, Z W Wong, N S Wong, P C S Ang and B Chowbay

Pharmacogenomics J 2017 17: 337-343; advance online publication, March 15, 2016; 10.1038/tpj.2016.17

Abstract | Full Text

Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer

S P Gampenrieder, C Hufnagl, S Brechelmacher, F Huemer, H Hackl, G Rinnerthaler, F Romeder, C Monzo Fuentes, P Morre, C Hauser-Kronberger, B Mlineritsch and R Greil

Pharmacogenomics J 2017 17: 344-350; advance online publication, May 3, 2016; 10.1038/tpj.2016.25

Abstract | Full Text

Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery

M H Ung, C-H Sun, C-W Weng, C-C Huang, C-C Lin, C-C Liu and C Cheng

Pharmacogenomics J 2017 17: 351-359; advance online publication, March 15, 2016; 10.1038/tpj.2016.18

Abstract | Full Text

KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

A Rivero-Juarez, R Gonzalez, M Frias, B Manzanares-Martín, D Rodriguez-Cano, I Perez-Camacho, A Gordon, F Cuenca, A Camacho, J A Pineda, J Peña and A Rivero

Pharmacogenomics J 2017 17: 360-365; advance online publication, March 15, 2016; 10.1038/tpj.2016.19

Abstract | Full Text

Genetic variation in the alpha1B-adrenergic receptor and vascular response

A Adefurin, L V Ghimire, U Kohli, M Muszkat, G G Sofowora, C Li, R T Levinson, S Y Paranjape, C M Stein and D Kurnik

Pharmacogenomics J 2017 17: 366-371; advance online publication, April 19, 2016; 10.1038/tpj.2016.29

Abstract | Full Text

Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients

N Ben Fredj, R Gam, E Kerkni, A Chaabane, Z Chadly, N Boughattas and K Aouam

Pharmacogenomics J 2017 17: 372-377; advance online publication, April 19, 2016; 10.1038/tpj.2016.26

Abstract | Full Text

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina

G Moya, P Dorado, V Ferreiro, M E G Naranjo, E M Peñas-Lledó and A LLerena

Pharmacogenomics J 2017 17: 378-381; advance online publication, April 12, 2016; 10.1038/tpj.2016.27

Abstract | Full Text

Prevalence and implications of cytochrome P450 substrates in Massachusetts hospital discharges

T H McCoy, V M Castro, A Cagan, A M Roberson and R H Perlis

Pharmacogenomics J 2017 17: 382-385; advance online publication, May 10, 2016; 10.1038/tpj.2016.24

Abstract | Full Text

Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies OPEN

E C M Tonk, D Gurwitz, A-H Maitland-van der Zee and A C J W Janssens

Pharmacogenomics J 2017 17: 386-392; advance online publication, May 10, 2016; 10.1038/tpj.2016.34

Abstract | Full Text



Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort

T M Dodgen, C De J Labuschagne, A van Schalkwyk, F E Steffens, A Gaedigk, A D Cromarty, M Alessandrini and M S Pepper

Pharmacogenomics J 2017 17: 393; 10.1038/tpj.2017.20

Full Text

A supplement to Nature Biotechnology | Nature Medicine | Nature Reviews Drug Discovery

Medtech Dealmakers explores the dealmaking strategies of the growing medical technology industry, and provides in-depth analysis of emerging technologies, as well as showcase innovative companies seeking partners. Check out the latest issue for medtech dealmaking and financing trends in 2016, and diagnostics deals from the past year- particularly for immuno oncology applications.

Download the issue for FREE
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to The Pharmacogenomics Journal. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: